The debate around tracking infection/vaccine status for events is reminiscent of last year’s debate around privacy & contact tracing apps. Ultimately, the better countries' ability to track where infection is/isn’t, the lower their COVID risk will be. 1/
If people don’t want to collect/use data in this way, they need to accept the trade off will be a higher COVID risk in the community (or more disruptive measures to prevent that risk). 2/
Many countries have implicitly chosen to introduce stay-at-home orders or live with higher numbers of cases rather than use detailed surveillance (e.g. to identify infections linked to superspreading events or enforce quarantine). 3/
You might agree with that trade off, you might not, but it’s a choice that will need to be made and it’s not helpful to pretend otherwise. 4/4
• • •
Missing some Tweet in this thread? You can try to
force a refresh
This is an interesting perspective on Taiwan (& glad it mentions data/privacy), although I'd like to see more references to what local officials were actually saying about approach in real-time, rather than what UK-based researchers later say it was: theguardian.com/world/2021/mar… 1/
E.g. from April 2020: "Covid-19 is becoming flu-like. It means that since it is highly contagious with many mild or asymptomatic cases, and can be transmitted through droplets and contaminated areas, we won’t get rid of this virus totally." telegraph.co.uk/global-health/… 2/
Taiwan has implemented several innovative, effective measures against COVID-19, but it will harm our ability to plan for the next pandemic if we don't look fully at how countries were interpreting - and acting on - available evidence in real-time. 3/
Is “we couldn’t have predicted the emergence of B117” a scientifically accurate statement? 1/
I’d argue it depends whether statement is interpreted in general or specific terms. “We couldn’t have predicted the possibility of a phenotypically distinct SARS-CoV-2 variant” is clearly inaccurate (given some adapation would have been involved in its original emergence)... 2/
...but “we couldn’t have predicted a variant emerging when it did in autumn 2020 with B117’s specific characteristics” is entirely reasonable (especially as our knowledge of its characteristics is still developing). 3/
Slogans aside, there are three broad approaches to COVID countries can take from now on:
A. An R<<1 approach
B. An R<1 approach
C. An R>1 approach
Let's break them down... 1/
A. An R<<1 approach means keeping R as low as possible with stringent measures until no local transmission. E.g. this is what Auckland and Melbourne did recently in response to a handful of new cases. 2/
B. An R<1 approach means keeping epidemic declining, although transmission may still continue for a long time as measures are relaxed. As coverage increases, vaccination could also 'buy' some additional reduction in R & allow more reopening under such an approach. 3/
What could happen next with novel variants like P.1 in the UK? There are four possible scenarios. A short thread with some thoughts... 1/
Scenario A: R<1 for both dominant B.1.1.7 variant and other variants of concern like P.1. This is likely situation we're currently in, but staying there is conditional on slow relaxation of control & substantial reduction in infectiousness via vaccines.
I sometimes see people making the mistaken assumption that once a group that make up X% of COVID hospitalisations/deaths are vaccinated, it will reduce hospitalisations/deaths by the same %, even if control measures are lifted. There are two main problems with this... 1/
First, there is a trade off between level of infection in the population and risk reduction through vaccination. Disease outcomes (e.g. hospitalisations/deaths) can broken down into the following: new infections x average-risk-per-infection... 2/
If we remove 50% of the hospitalisation risk within a population through vaccination, for example, but have a large increase in level of infection, it could mean no reduction (or even an increase) in overall hospitalisations... 3/
As with influenza, they find a 'ladder-like' phylogenetic tree, suggesting that new variants emerge, become dominant, then are gradually replaced by subsequent new variants. (Influenza A/H3N2 below right from: nature.com/articles/natur…) 3/